Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer

The use of immune adjuvants such as toll-like receptor (TLR) agonists reflects a novel strategy in prostate cancer (PCa) therapy. However, interleukin-1 receptor associated kinase 1 (IRAK1), a central effector of TLR signaling, has been shown to be responsible for resistance to radiation-induced tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Schagdarsurengin, Undraga, Breiding, Vanessa, Loose, Maria, Wagenlehner, Florian, Dansranjav, Temuujin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549294/
https://www.ncbi.nlm.nih.gov/pubmed/36226067
http://dx.doi.org/10.3389/fonc.2022.991368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549294/
https://www.ncbi.nlm.nih.gov/pubmed/36226067
http://dx.doi.org/10.3389/fonc.2022.991368

Ejemplares similares